Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.

Gynecologic oncology

Volumn 134, Issue 3, 2014, Pages 607-614

  Laskov, Ido ^a   Drudi, Laura ^a   Beauchamp, Marie Claude ^a   Yasmeen, Amber ^a   Ferenczy, Alex ^a   Pollak, Michael ^a   Gotlieb, Walter H ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; SOMATOMEDIN; TUMOR MARKER;

AGED; AMPK; ARTICLE; BLOOD; CELL PROLIFERATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM TUMOR; FEMALE; HUMAN; KI-67; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PROSPECTIVE STUDY; PS6;

AMPK; ENDOMETRIAL CANCER; INSULIN GROWTH FACTOR; KI-67; METFORMIN; PS6;

AGED; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84908342070     PISSN: None     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.06.014     Document Type: Article

References (0)